Pediatric Disease Registry in Essential Thrombocythaemia (ET)

N/ACompletedNCT01198717

Shire60 enrolled

Overview

The aim of this study is to evaluate the progression of ET in children (aged 6-17years inclusive) over a period of 5 years maximum. The study will also assess how children are diagnosed, treatment options for those children with symptoms and events related to their ET and the outcomes of those treatments.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Essential Thrombocythemia (ET)

Eligibility

Sex: ALLMin age: 6 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- 6 years or over and less than 18 years patient has ET according to the WHO criteria as guidance Exclusion Criteria: * Interventional clinical study participation

Locations (32)

Outcomes

Primary Outcomes

Treatment effects on platelet count in children ages 6-17 years inclusive.

Time frame: 60 months

Secondary Outcomes

Drug utilization of cytoreductive therapy in children ages 6-17 years inclusive

Time frame: 60 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Paediatric Clinic University Hospital Olomouc

Olomouc, Czechia

Clinic of Paediatric haematology and oncology University Hospital Motol

Prague, Czechia

Paediatric Oncology Unit, Hopital Cote De Nacre

Caen, France

Practicen Hospitalier , Institute d'Hematologie et Oncologie Pediatrique

Lyon, France

Centre Hospitalier Lyon Sud - service Hématologie

Pierre-Bénite, France

Hopitaux de Brabois

Vandœuvre-lès-Nancy, France

Klinikum Chemnitz GmbH, Klinik für Kinder-und Jugendmedizin

Chemnitz, Germany

Zentrum für Kinder- und Jugendmedizin Klinik II / III

Frankfurt, Germany

"Agia Sophia" Children's Hospital

Athens, Greece

Dipartimento di Biomedicina dell'Eta Evolutiva. University of Bari

Bari, Italy

...and 22 more locations